Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests.
It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University.
Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 24 | -0.09 Increased by +80.00% | -0.32 Increased by +71.88% |
| May 8, 24 | -0.60 Decreased by -42.86% | -0.47 Decreased by -27.66% |
| Feb 21, 24 | -0.27 Increased by +62.50% | -0.46 Increased by +41.30% |
| Nov 1, 23 | 0.00 Increased by +100.51% | -0.48 Increased by +100.90% |
| Aug 1, 23 | -0.45 Increased by +45.78% | -0.51 Increased by +11.76% |
| May 9, 23 | -0.42 Increased by +59.62% | -0.75 Increased by +44.00% |
| Feb 21, 23 | -0.72 Increased by +43.75% | -0.84 Increased by +14.29% |
| Nov 3, 22 | -0.84 Increased by +13.40% | -1.08 Increased by +22.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 708.65 M Increased by +12.78% | -38.24 M Decreased by -4.92 K% | Decreased by -5.40% Decreased by -4.37 K% |
| Jun 30, 24 | 699.26 M Increased by +12.41% | -15.81 M Increased by +80.49% | Decreased by -2.26% Increased by +82.64% |
| Mar 31, 24 | 637.52 M Increased by +5.82% | -110.23 M Decreased by -48.65% | Decreased by -17.29% Decreased by -40.48% |
| Dec 31, 23 | 646.88 M Increased by +16.98% | -49.77 M Increased by +61.04% | Decreased by -7.69% Increased by +66.70% |
| Sep 30, 23 | 628.34 M Increased by +20.12% | 794.00 K Increased by +100.53% | Increased by +0.13% Increased by +100.44% |
| Jun 30, 23 | 622.09 M Increased by +19.26% | -81.03 M Increased by +51.21% | Decreased by -13.02% Increased by +59.09% |
| Mar 31, 23 | 602.45 M Increased by +23.82% | -74.15 M Increased by +59.02% | Decreased by -12.31% Increased by +66.90% |
| Dec 31, 22 | 553.00 M Increased by +16.71% | -127.75 M Increased by +42.09% | Decreased by -23.10% Increased by +50.39% |